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S U M M A R Y
Objectives: This study sought to assess the West Nile Virus (WNV) seroprevalence and behavioral risk
factors for WNV infection in HIV-1 infected individuals in Northern Greece in 2011.
Methods: We prospectively enrolled 91 HIV-1 consecutive patients followed up in the HIV clinic of the
AHEPA University Hospital in the period from November to December 2011. Serum samples were tested
for the presence of WNV IgG antibodies. All subjects were administered a standardized questionnaire to
evaluate for risk factors for WNV infection.
Results: WNV IgG antibodies were detected in three subjects (3.3%, 95% CI 0.7-9.3%), two of whom were
of African origin. The prevalence of WNV antibodies in HIV patients of Greek origin was 1.2% (95% CI:
0.03% - 6.3%). In the sample surveyed, 53.6% (95% CI: 42.4% to 64.5%) were aware of WNV prevention
measures; 2.2% reported no implementation of prevention measures, whereas 46.1% implemented at
least three measures. Approximately one half of the patients reported outdoor activities for more than
two hours from dusk to dawn. None of the IgG-positive patients reported any symptoms compatible with
WNV disease during the season at risk.
Conclusions: Among native Greek HIV patients, the WNV seroprevalence is 1.2%. A considerable
proportion of patients was aware of WNV prevention measures and implemented some of these. HIV
patients and other categories of immunocompromised patients are at increased risk of neuroinvasive
disease, and widespread implementation of prevention measures should be strongly encouraged in this
patient population.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idA large outbreak of West Nile virus (WNV) infections occurred
in Greece in 2010; the epicenter was in Central Macedonia,
northern Greece, where 197 cases of WNV neuroinvasive disease
(WNND) were documented.1 A resurgence of WNV outbreaks was
observed in 2011 and 2012, with 75 and 109 WNND cases,
respectively.2 Sequences obtained from patients identiﬁed WNV
lineage 2.3
WNND in HIV patients has been described infrequently;
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).case in an HIV patient.4 The occurrence of a WNV encephalitis case
in a 35-year old male HIV-1 patient followed up by the HIV clinic in
AHEPA University Hospital in Thessaloniki (S. Metallidis, unpub-
lished data) prompted a seroprevalence study in a cohort of HIV-1
infected patients. This study was accompanied by checking the
behavioral risk factors for WNV infection in order to estimate the
extent of exposure of HIV patients to the virus and to evaluate the
risk factors in this speciﬁc patient population.
We prospectively enrolled 91 HIV-1 consecutive patients
(followed up in the HIV clinic of the AHEPA University Hospital),
who presented for routine follow-up between November and
December 2011, corresponding to 13.3% of individual patients
presenting for care from October 2011 to March 2012. The study was
designed to have 80% power to detect an increase of the WNV
seroprevalence from 1% to 5%. The baseline of 1% WNV seropreva-
lence was based on a study conducted during 2004-2006, which
indicated a WNV seroprevalence of 0.62% among apparently healthyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 2
Demographic and laboratory data from 3 WNV IgG-positive HIV-1 patients
Patient Sex Age Origin WNV IgM
Cut-off 1.1
WNV IgG
Cut-off 1.5
WNV IgG
avidity*
1 Male 64 Greek 1.3 3.01 100%
2 Male 35 African Negative 3.77 100%
3 Female 31 African Negative 3.68 90%
* IgG avidity >60% suggests a past infection (>6 months).
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northern Greece (Pella and Imathia), after the 2010 epidemic,
estimated that 5.8% of the population had been exposed to the WNV.6
The AHEPA HIV clinic is the single centre to provide HIV care in
the region of Central Macedonia (epicenter of the WNV 2010 epi-
demic), but also in the wider region of northern Greece, which was
affected in 2011. The study was approved by the Bioethics
Committee of Aristotle University of Thessaloniki, and informed
consent was a prerequisite to study enrollment.
Serum samples were tested for the presence of WNV-speciﬁc
IgG and IgM antibodies (DxSelect, Focus Diagnostics Inc, Cypress,
CA, USA). IgG avidity test was performed to discriminate between
recent and past infection. The IgG positive samples were tested by
neutralization test (PRNT90). Demographic and clinical data were
retrieved from the patient database.
All enrolled patients were administered a standardized
questionnaire about established risk factors for WNV infections
(Table 1) and history of hospitalization for neurological symptoms
during the previous epidemic period.
Binomial exact 95% conﬁdence intervals were calculated for
proportions. Differences between WNV IgG-positive and -negative
participants were evaluated using the Fisher exact test.
Three patients had WNV IgG antibodies (3.3%, 95% CI: 0.7% to
9.3%). The ELISA results were conﬁrmed by neutralization test. The
IgG avidity was 90-100%, suggestive of a past infection. A low titre of
WNV IgM antibodies was present in one patient (Table 2). Two of
them (one male) were of African origin, and had been residents of
Thessaloniki (urban area) for 4 years, and one (male) was Greek, a
resident of a village in Pella prefecture (rural area) who had no
history of travel abroad. Except for immigrant status (p = 0.007), no
other epidemiological characteristic or behavioral risk factor was
signiﬁcantly associated with WNV seropositivity. Given that the
WNV IgG antibodies persist for long time, it cannot be excluded that
the two patients of African origin had acquired the WNV infection in
Africa. Thus, among the 86 Greek HIV-1 patients, only one (1.2%, 95%
CI: 0.03 – 6.3%) carried WNV antibodies. Although the observed
seroprevalence was low, it is of interest that the Greek IgG-positive
patient was resident of Pella prefecture, that with the highest WNV
incidence in 2010 (28.26 per 100,000 population);1 in total,
3 patients were tested from this geographic region.
Despite a campaign organized by the Hellenic Centre for
Disease Control and Prevention to inform the public aboutTable 1
Epidemiological and behavioral risk factors for WNV infection
Factor N/total (%)
Residence
Thessaloniki city 55/91 (60.4%)
Central Macedonia (other than Thessaloniki) 16/91 (17.6%)
Thessaly 14/91 (15.4%)
West Macedonia 2/91 (2.2%)
Unknown 4/91 (4.4%)
Urban area 70/91 (76.9%)
Mostly indoor professional activity 63/79 (79.7%)
Awareness of prevention measures 45/84 (53.6%)
Measures implemented
Window screens 43/85 (50.6%)
Use of fans/air conditioning 34/84 (40.5%)
Mosquito repellents 55/85 (64.7%)
Draining standing water/
taking care of grass /vegetated areas
56/85 (65.9%)
Protective clothing 58/85 (68.2%)
Keeping birds/poultry 5/86 (5.8%)
Homeless 0/86 (0%)
Outdoor exposure from dusk till dawn
Less than 1h 11/91 (12.1%)
1-2 hours 21/91 (23.1%)
More than 2h 48/91 (52.7%)
Unknown 11/91 (12.1%)measures to prevent WNV infection, only 53.6% (95% CI: 42.4%
to 64.5%) of the population surveyed was aware of prevention
measures (Table 1). Nevertheless, only 2.2% reported no imple-
mentation of prevention measures and 46.1% reported implemen-
tation of at least 3 of the 5 prevention measures included in the
questionnaire. Approximately half of the patients (52.7%) reported
engaging in outdoors activities for more than 2 hours from dusk to
dawn. None of the IgG-positive patients reported any symptoms
compatible with WNV disease during the season at risk. To our
knowledge, no additional measures were implemented to inform
speciﬁc at-risk populations, such as the HIV patients.
In conclusion, a WNV seroprevalence of 1.2% was observed
among native HIV-1 patients in northern Greece following two
WNV seasons, a rate that is low compared with that observed
among HIV-negative persons (5.8%) following one WNV season.6
This difference might reﬂect differences in the study sample, which
in our study consisted predominantly of young male individuals
who resided in urban areas.
Current data indicate that immunocompromised patients are at
increased risk for severe WNV disease.7,8 However, the literature
with regard to the HIV infected population is limited. Similarly in
northern Greece, where large outbreaks took place during the last
4 years, we were not able to draw any conclusion about severity of
the disease among HIV-1 patients, since only one WNV case was
observed in this population group. According to a recent report,
CD4 gene expression is decreased by human ﬂavivirus (including
WNV) NS5 proteins, and it has been suggested that CD4 regulation
by ﬂaviviruses may interfere with innate and adaptive immunity,
inhibiting the HIV replication in human CD4+ cells.9 Furthermore,
CCR5 is beneﬁcial in host defense against WNV infection but
harmful in facilitating HIV infection.10 Understanding the inter-
actions between WNV and HIV may lead to novel therapeutic
strategies.10 Apart from the research studies, because HIV patients
are immunocompromised, they are at increased risk of acquiring a
WNND, and the simplest way to eliminate the risk of infection is to
increase awareness and to implement prevention measures to
avoid mosquito bites.
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